Effect of atropine and somatostatin on bombesin-stimulated plasma immunoreactive trypsin release in man.

  title={Effect of atropine and somatostatin on bombesin-stimulated plasma immunoreactive trypsin release in man.},
  author={A. D. de Jong and M. Klamer and C. Lamers},
  volume={37 3},
This study was undertaken to determine the effect of atropine and somatostatin, two inhibitors of intraduodenal pancreatic enzyme secretion, on bombesin-stimulated release of plasma immunoreactive trypsin in 6 healthy volunteers. Infusion of 5 ng/kg.min bombesin during 30 min induced significant increases in plasma trypsin from 206 +/- 20 to 334 +/- 44 ng/ml (p less than 0.01). Atropine (15 ng/kg as i.v. bolus followed by 5 ng/kg.h) had no influence on the bombesin-stimulated increase in plasma… Expand
3 Citations
Low‐titer antibodies reactive with HTLV‐I gag P19 in patients with chronic myeloneuropathy
The results suggest that in some patients chronic myeloneuropathy diagnosed as chronic progressive multiple sclerosis, chronic progressive myelopathy, and chronic inflammatory polyradicul oneuropathy may be associated with HTLV‐I or related retroviruses. Expand
Seroprevalence of antibodies to HTLV‐I In patients with chronic neurological disorders other than tropical spastic paraparesis
The data indicate that HTLV‐I is an unlikely causative agent in the spectrum of the neurological diseases examined, except for the high seropositivity rate among the group of Jamaican patients with polymyositis. Expand
HTLV‐I sequences are not detected in peripheral blood genomic DNA or in brain cDNA of multiple sclerosis patients
Comparison of DNA amplification patterns between patients with MS, and with control subjects who have other autoimmune conditions, with those in healthy control subjects and with an HTLV‐I‐infected cell line indicates that HTLV-I pol sequence is not present in the peripheral blood of patients withMS, and that the virus is not active in MS brain plaques. Expand